Plain-English translation of NCT06579196 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two intravenous medications — (OT-101) and — to see if they work better together for treating advanced non-small cell lung cancer. In the first phase, researchers will figure out the right dose of when combined with and check for side effects. In the second phase, they'll see whether this medication combination can slow down or stop the cancer from growing.
is already approved for lung cancer, but researchers want to see if adding to the treatment might make it work better and help more patients live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
You would receive intravenously for 4 consecutive days every 2 weeks (with 10 days off between treatment cycles), and intravenously once every 6 weeks. You'll need to visit the clinic for each infusion and to have it disconnected. In the first phase, researchers will test different doses to find the safest and most effective one; in the second phase, you'll continue taking the medication at that dose until your cancer stops responding or progresses. The trial also includes regular check-ins and scans to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States